(To see other currencies, click on price)
MORE ABOUT THIS BOOK
Main description:
One of the most important developments in the field of cardiovascular medicine over the last two decades has been recognition of the key role played by arterial thrombosis in the pathogenesis of acute coronary syndromes, ischemic complications of percutane- ous coronary revascularization, and coronary and peripheral atherosclerosis. The phar- macologic armamentarium directed against vascular thrombosis has thus expanded substantially during that time, with development of new fibrinolytic agents, low-molecu- lar-weight heparins, direct thrombin inhibitors, antagonists to platelet activation, and the platelet glycoprotein lIb/IlIa inhibitors. Though clinical investigations of these com- pounds have been marked by failures as well as successes, there is little doubt that enhanced antithrombotic therapies have markedly improved the outcome of patients undergoing coronary revascularization or with acute coronary syndromes. Glycoprotein IIblIlIa receptor antagonists were introduced into clinical practice to overcome the limitations of approaches that inhibit only individual pathways of platelet activation.
Multiple mechanisms of platelet activation in response to different agonists converge on the platelet membrane glycoprotein IIblIlIa complex, the "final common pathway" of platelet aggregation. The clinical hemorrhagic syndrome caused by a rare inherited defect in this receptor (Glanzmann' s thrombasthenia), characterized by muco- cutaneous and postsurgical bleeding, but infrequent spontaneous organ (particularly central nervous system) bleeding, suggested that therapeutic inhibition of this receptor might be a potent, yet well-tolerated means of treating thrombotic disorders.
Contents:
Part I. Basic Principles
Thrombosis in Acute Coronary Syndromes and Coronary Interventions
Thaddeus R. Tolleson and Robert A. Harrington
Platelet Adhesion
Edward F. Plow
Glycoprotein IIb/IIIa in Platelet Aggregation and Acute Arterial Thrombosis
Patrick Andre and David R. Phillips
Glycoprotein IIb/IIIa Antagonists: Development of Abciximab and Pharmacology of Abciximab
Tirofiban, and Eptifibatide, Barry S. Coller
Part II. Glycoprotein IIb/IIIa Blockade During Coronary Intervention
Abciximab During Percutaneous Coronary Intervention: EPIC, EPILOG, and EPISTENT Trials
A. Michael Lincoff
Eptifibatide in Coronary Intervention: The IMPACT and ESPRIT Trials
Jean-Pierre Dery, J. Conor O'Shea, and James E. Tcheng
Tirofiban in Interventional Cardiology: The RESTORE and TARGET Trials
Nicholas Valettas and Howard C. Herrmann
Overview of the Glycoprotein IIb/IIIa Interventional Trials
A. Michael Lincoff and Eric J. Topol
Part III. Glycoprotein IIb/IIIa Blockade for Acute Ischemic Syndromes
The Use of Abciximab in Therapy-Resistant Unstable Angina: Clinical and Angiographic Results of the CAPTURE Pilot Trial and the CAPTURE Study
Marcel J. B. M. van den Brand and Maarten L. Simoons
Unstable Angina Trials: PARAGON, PURSUIT, PRISM, PRISM-PLUS, and GUSTO-IV
David J. Moliterno
Platelet Glycoprotein IIb/IIIa Inhibitors and an Invasive Strategy
Christopher P. Cannon
Glycoprotein IIb/IIIa Receptor Blockade in Myocardial Infarction: Adjunctive Therapy to Percutaneous Coronary Interventions
Franz-Josef Neumann
Glycoprotein IIb/IIIa Receptor Blockade in Acute Myocardial Infarction: Adjunctive Therapy to Fibrinolysis
Sorin J. Brener
Part IV. Practical Issues and Future Applications
Economics of Glycoprotein IIb/IIIa Inhibition
Daniel B.Mark
Platelet Monitoring and Interaction of Glycoprotein IIb/IIIa Antagonists with Other Antiplatelet Agents
Steven R. Steinhubl
Platelet Glycoprotein IIb/IIIa Antagonists: Their Interaction with Low-Molecular-Weight Heparins and Direct Thrombin Inhibitors
Amol S. Bapat, Naji Yazbek, and Neal S. Kleiman
Oral Agents
L. Kristin Newby
Platelet Glycoprotein IIb/IIIa Inhibitors: Effects Beyond the Platelet
Dean J. Kereiakes and Pascal J. Goldschmidt-Clermont
Cerebrovascular Interventions
Leslie Cho and Jay S. Yadav
Cerebrovascular Aspects of Glycoprotein IIb/IIIa Receptor Inhibitors
Cathy A. Sila
Evolution of Drug Development in Evidence-Based Medicine: Summary and the Future
David E. Kandzari, David F. Kong, and Robert M. Califf
Index
PRODUCT DETAILS
Publisher: Springer (Humana Press Inc.)
Publication date: November, 2010
Pages: 486
Weight: 920g
Availability: Available
Subcategories: Cardiovascular Medicine
From the same series
